Research ArticleIMMUNOTHERAPY

Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome

See allHide authors and affiliations

Science Immunology  17 Jan 2020:
Vol. 5, Issue 43, eaax7969
DOI: 10.1126/sciimmunol.aax7969

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Gasdermin E as troublemaker

Cytokine release syndrome (CRS) is a complication associated with chimeric antigen receptor (CAR) T cell therapy in cancer patients. The mechanisms that trigger CRS are not clear, but Liu et al. describe a role for the pore-forming protein gasdermin E (GSDME) during tumor cell pyroptosis, which contributes to CRS. CAR T cells release granzyme B, which activates caspase 3 and cleaves GSDME in target tumor cells and causes pyroptosis. Pyroptosis by GSDME leads to activation of caspase 1 and GSDMD in macrophages, which is critical for triggering CRS. Elevated levels of GSDME in cancer patients positively correlated to CRS severity. In addition, the ability of CAR T cells to induce pyroptosis is associated with the levels of perforin and granzyme B released.

View Full Text

Stay Connected to Science Immunology